Northland Capmk Has Pessimistic View of HRTX Q4 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Northland Capmk lowered their Q4 2024 EPS estimates for shares of Heron Therapeutics in a report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.08) per share.

A number of other research firms have also recently issued reports on HRTX. StockNews.com upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Needham & Company LLC decreased their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday.

Heron Therapeutics Trading Down 4.0 %

Heron Therapeutics stock opened at $1.19 on Friday. The stock has a market cap of $180.99 million, a P/E ratio of -6.61 and a beta of 1.81. Heron Therapeutics has a 52 week low of $0.81 and a 52 week high of $3.93. The stock has a 50 day moving average of $1.82 and a 200-day moving average of $2.51.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period last year, the firm posted ($0.17) earnings per share.

Institutional Trading of Heron Therapeutics

Several institutional investors have recently made changes to their positions in HRTX. Congress Park Capital LLC increased its holdings in Heron Therapeutics by 25.3% in the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after buying an additional 399,577 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Heron Therapeutics by 369.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 286,160 shares in the last quarter. BNP Paribas Financial Markets increased its position in Heron Therapeutics by 80.7% during the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company’s stock worth $142,000 after buying an additional 22,904 shares during the last quarter. Marshall Wace LLP raised its holdings in Heron Therapeutics by 256.2% during the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after buying an additional 1,266,697 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,328 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.